<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140569">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271010</url>
  </required_header>
  <id_info>
    <org_study_id>ML25136</org_study_id>
    <nct_id>NCT01271010</nct_id>
  </id_info>
  <brief_title>A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status</brief_title>
  <official_title>Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center, single-arm study will evaluate the efficacy and safety of rituximab in
      combination with fludarabine and cyclophosphamide in participants with B-cell chronic
      lymphocytic leukemia (CLL) and favorable somatic status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Therapy Response (Complete Remission, Partial Remission, Stable Disease, and Disease Progression) as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology</measure>
    <time_frame>Baseline until disease progression or death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology</measure>
    <time_frame>Baseline until disease progression or death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline until death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology</measure>
    <time_frame>Baseline until disease progression or death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology</measure>
    <time_frame>Baseline until disease progression or death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Primary Resistance to Therapy</measure>
    <time_frame>Baseline until disease progression or death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity</measure>
    <time_frame>Baseline until disease progression or death due to any cause (up to approximately 60 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline up to approximately 60 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Lymphocytic Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>Rituximab + Fludarabine + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive, rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration is 6 cycles, 28 days each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Participants will receive cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle.</description>
    <arm_group_label>Rituximab + Fludarabine + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Participants will receive fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle.</description>
    <arm_group_label>Rituximab + Fludarabine + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Participants will receive, 375 mg/m^2 IV on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle.</description>
    <arm_group_label>Rituximab + Fludarabine + Cyclophosphamide</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of previously untreated B-cell CLL confirmed immunophenotypically

          -  For participants, age 60-70 years: Cumulative Illness Rating Scale (CIRS) comorbidity
             score less than or equal to (&lt;/=) 6

          -  Binet stage B, C or A with progression

          -  Life expectancy greater than or equal to (&gt;/=) 12 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  Women of child bearing potential and men should agree to use highly reliable
             contraceptive method throughout the treatment period and within 12 months after
             treatment completion

        Exclusion Criteria:

          -  Participants with small-cell lymphoma

          -  Participants with auto-immune hemolytic anemia

          -  Concomitant malignant disease during enrollment, except basal cell carcinoma of the
             skin

          -  Chemotherapy for concomitant malignant disease given within 12 months prior to study
             enrollment

          -  Participants with Richter's Syndrome

          -  Participants with symptomatic Hepatitis B infection

          -  Any clinically significant infection that could not be cured prior to enrollment,
             including Human Immunodeficiency Virus (HIV) infection

          -  Creatinine clearance less than (&lt;) 30 milliliters per minute (mL/min)

          -  Participants with congestive heart failure (CHF) New York Heart Association (NYHA)
             III-IV

          -  Participants with liver failure and acute hepatitis of any etiology

          -  Any other medical or mental condition which may preclude from receiving the entire
             course of protocol specified treatment or signing the informed consent

          -  History of an anaphylactic reaction to murine antibodies, proteins, or any other
             ingredient of rituximab

          -  Pregnancy and breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Irkutsk</city>
        <zip>664079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>UFA</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>January 4, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
